Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation reports developments as a medical technology company focused on minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. Its commercial platform includes the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform and StratX Lung Analysis Reports, which are designed to assess and treat symptomatic severe emphysema/COPD patients. The Zephyr Valve received FDA premarket approval after breakthrough device designation and is commercially available in more than 25 countries.
Recurring Pulmonx news covers quarterly and annual financial results, U.S. and international revenue trends, gross margin, commercial execution, clinical program activity, debt refinancing, cost initiatives, inducement equity awards and governance or leadership changes.
Pulmonx Corporation (LUNG) reported a 25% increase in worldwide revenue for Q3 2021, totaling $13.3 million, compared to $10.6 million in Q3 2020. The gross margin improved to 73% from 70% year-over-year. U.S. revenue rose 28% to $6.9 million. Operating expenses surged 52% to $19.5 million, leading to a net loss of $10.2 million or $0.28 per share. Pulmonx maintains its full-year revenue guidance of $49 to $51 million, amid ongoing COVID-19 uncertainties.
Pulmonx Corporation (Nasdaq: LUNG) will release its third quarter 2021 financial results on November 2, 2021, post-market. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Investors can join the call by dialing (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 9545716. Pulmonx is known for its minimally invasive treatments for lung diseases, including the Zephyr® Endobronchial Valve, which has been used in over 25,000 patients worldwide.
Pulmonx Corporation (NASDAQ: LUNG) announced that Blue Cross Blue Shield of Michigan and Horizon BCBS of New Jersey have issued positive coverage policies for the Zephyr® Endobronchial Valve, a treatment for severe emphysema. This gives access to nearly 10 million covered lives, adding to existing BCBS coverage for 69 million members. The Zephyr Valve is minimally invasive and improves lung function without the risks of major surgery. More than 25,000 patients have been treated with the valve globally, with significant clinical backing.
Pulmonx Corporation (Nasdaq: LUNG) announced its participation in two virtual investor conferences. Management will engage in fireside chats at the 2021 Virtual Wells Fargo Healthcare Conference on September 9, 2021, at 7:00 AM PT and the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 1:15 PM PT. Interested parties can access live and archived webcasts on the Pulmonx website. Pulmonx is known for its minimally invasive treatments for severe lung diseases, including the Zephyr Endobronchial Valve, which has received FDA approval and is available in over 25 countries.
Pulmonx Corporation (Nasdaq: LUNG) announced that Anthem Blue Cross Blue Shield has issued a positive coverage policy for its Zephyr® Valve, a minimally invasive treatment for severe emphysema, affecting 34 million lives. This adds to existing coverage from other BCBS plans, totaling 59 million covered members in the US. The Zephyr Valve improves lung function, exercise capacity, and quality of life, with over 20,000 patients treated globally. Glen French, CEO of Pulmonx, praised the decision as a significant advancement for patients suffering from severe breathlessness.
Pulmonx Corporation (LUNG) reported a 232% increase in Q2 2021 revenue, reaching $12.2 million, due to recovering procedure volumes post-COVID-19. Gross margin improved to 74% from 28% in the prior year. U.S. revenue surged 343% to $6.6 million, while international revenue rose 157% to $5.6 million. Despite increased operating expenses of $21.1 million, the company continues to invest in growth. Pulmonx raised its full-year revenue guidance to $49-$51 million, signaling 50%-56% growth over 2020.
Pulmonx Corporation (Nasdaq: LUNG) has appointed Alissa Hsu Lynch and Tiffany Sullivan to its Board of Directors as of July 29, 2021. Lynch, with over 20 years of experience in MedTech and consumer marketing, currently leads MedTech Strategy and Solutions for Google Cloud. Sullivan serves as COO of Physician Services at New York-Presbyterian Hospital, bringing extensive healthcare delivery experience. Their appointments are expected to enhance Pulmonx's ability to scale its innovative treatments for chronic lung diseases.
Pulmonx Corporation (Nasdaq: LUNG) will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 8:30 AM PT / 11:30 AM ET. Interested individuals can access a live and archived webcast on Pulmonx's website. Pulmonx is known for its minimally invasive treatments for severe lung diseases, particularly its Zephyr® Endobronchial Valve, which received FDA pre-market approval as a breakthrough device. The Zephyr Valve is available in over 25 countries and has been used in more than 20,000 patients.
Pulmonx Corporation (Nasdaq: LUNG) published long-term follow-up data from the IMPACT Study, showcasing the Zephyr® Valve's effectiveness for patients with severe COPD/emphysema and homogenous disease distribution. The study highlights significant benefits over 12 months, including improved lung function (FEV1), increased quality of life (SGRQ), enhanced exercise capacity (6MWD), and reduced hyperinflation. This minimally invasive treatment is the only FDA-approved option for this patient group, providing much-needed relief where traditional medications fail.
Pulmonx Corporation (Nasdaq: LUNG) will release its Q2 2021 financial results on August 3, 2021, after the market closes. A conference call for this announcement will follow at 1:30 p.m. PT / 4:30 p.m. ET. Investors can join by calling (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 5682784. Pulmonx is a leader in minimally invasive treatments for severe lung disease, notably with its Zephyr Endobronchial Valve, used to treat over 20,000 patients globally.